The Management Board of Selvita S.A. with its registered office in Krakow (“Selvita”) hereby announces that the company affiliated with Selvita – Fidelta d.o.o. (“Fidelta”) with its registered office in Zagreb, Croatia has concluded on 22nd September 2021 a framework agreement (“Agreement”) between Fidelta and a biotechnological company with its registered office in the UK (“Client”) under which the Client committed itself to spent at least EUR 1,200,000 (PLN 5,556,960 converted at the rate EUR 1 = PLN 4.6308) within next 12 months on services to be delivered by Fidelta. The Agreement is an extension of the ongoing collaboration between the parties that was established in 2013.

The objective of the Agreement is multiple FTE based integrated collaboration to support Client’s drug discovery projects. Fidelta, in its laboratories in Zagreb, will provide services in the area of in vitro and in vivo Pharmacology; ADME, DMPK and translational studies based on patient samples study.

Taking into account value of the minimal commitment to purchase Fidelta’s services, its scope, as well the fact that the Client has further extended cooperation with Fidelta, the Company’s Management Board considers this Agreement to be significant for the implementation of Selvita Group’s long-term plans aiming at building a strong position on the international preclinical CRO (Clinical Research Organization) market.

Legal basis: Art. 17 par. 1 of MAR

Representatives of the Company:     

  • Bogusław Sieczkowski – President of the Management Board
  • Dawid Radziszewski – Member of the Management Board